In the Journals

ACE inhibitor use increases bone loss in older men

Kwok T. Osteoporos Int. 2011. doi: 10.1007/s00198-011-1831-7

The use of angiotensin-coverting enzyme inhibitors can marginally increase bone loss in older men, according to this study from researchers in Hong Kong.

The team examined a cohort of 5,995 American men (65 years of age or older) across six different centers who participated in The Osteoporotic Fractures in Men Study. Overall, 5,229 of these men were reported as having an average of 4.6 years of follow up and 3,494 were eligible subjects with complete data. According to the study abstract, 1,166 of these patients used angiotensin-converting enzyme (ACE) inhibitors and 433 reported using angiotensin II AT1 receptor blockers (ARB).

Hologic densitometer was used to measure bone mineral densities (BMD) at the total hip, femoral neck and trochanter.

“When compared with nonusers, continuous use of ACE inhibitors was associated with a small but significant increase in the average rate of BMD loss at total hip and trochanter over 4 years after adjustment for confounders,” the authors wrote, adding that the use of ARB was not found to be associated with bone loss.

The use of angiotensin-coverting enzyme inhibitors can marginally increase bone loss in older men, according to this study from researchers in Hong Kong.

The team examined a cohort of 5,995 American men (65 years of age or older) across six different centers who participated in The Osteoporotic Fractures in Men Study. Overall, 5,229 of these men were reported as having an average of 4.6 years of follow up and 3,494 were eligible subjects with complete data. According to the study abstract, 1,166 of these patients used angiotensin-converting enzyme (ACE) inhibitors and 433 reported using angiotensin II AT1 receptor blockers (ARB).

Hologic densitometer was used to measure bone mineral densities (BMD) at the total hip, femoral neck and trochanter.

“When compared with nonusers, continuous use of ACE inhibitors was associated with a small but significant increase in the average rate of BMD loss at total hip and trochanter over 4 years after adjustment for confounders,” the authors wrote, adding that the use of ARB was not found to be associated with bone loss.